


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
17530

In Re Application Of: **Robert James, et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/800,322	March 12, 2004	Dan Sung C. Cho	23389	1634	2289

Title: **NUCLEIC ACID MARKERS FOR USE IN DETERMINING PREDISPOSITION TO NEOPLASM
AND/OR ADENOMA**



Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
17530

In Re Application of: **Robert James, et al.**

Application No.
10/800,322

Filing Date
March 12, 2004


Examiner
Dan Sung C. Cho

Customer No.
23389

Group Art Unit
1634

Confirmation No.
2289

Title: **NUCLEIC ACID MARKERS FOR USE IN DETERMINING PREDISPOSITION TO NEOPLASM AND/OR ADENOMA**



Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date) _____

Signature _____

Typed or Printed Name of Person Signing Certificate _____

*This certificate may only be used if paying by deposit account.

Xiaochun Zhu
Signature

Xiaochun Zhu
Registration No. 56,311
Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
516-742-4343

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

January 11, 2007

(Date) _____

Xiaochun Zhu
Signature of Person Mailing Correspondence

Xiaochun Zhu
Typed or Printed Name of Person Mailing Certificate

Dated: January 11, 2007

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Robert James, et al..
Serial No.: 10/800,322
Filed: March 12, 2004
For: NUCLEIC ACID MARKERS FOR USE
IN DETERMINING PREDISPOSITION TO
NEOPLASM AND/OR ADENOMA

Examiner: Dan Sung C. Cho
Art Unit: 1634
Docket: 17530
Dated: January 11, 2007

Confirmation No.: 2289

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. First Office Action issued in respect of corresponding Australian Patent Application No. 2002325088 on October 26, 2005;
2. Supplementary Partial European Search Report dated May 2, 2005;
3. Supplementary Partial European Search Report dated January 25, 2006;

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: January 11, 2007


Xiaochun Zhu


4. SEQ ID NO: 13 of PCT International Publication No. WO 00/55371, published September 21, 2000;
5. SEQ ID NO: 17 of PCT International Publication No. WO 00/76530, published December 21, 2000;
6. Chan E-C, "Identification of Novel Genes that are Differentially Expressed in Human Colorectal Carcinoma", *Biochimica et Biophysica Acta* 1407(3):200-204 (1998), XP-000910494;
7. PCT International Publication No. WO 00/37643, published June 29, 2000;
8. SEQ ID NO: 7050 of PCT International Publication No. WO 01/075067, published October 11, 2001;
9. PCT International Publication No. WO 02/40720, published May 23, 2002; and
10. SEQ ID NOS: 1047 and 3703 of PCT International Publication No. WO 99/38972, published August 5, 1999.

Copies of the above references are enclosed.¹ Reference Nos. 4-9 were cited in a Supplementary Partial Search Report dated May 2, 2005 (Reference No. 2) received from the European Patent Office. Reference Nos. 4-10 were cited in a Supplementary Partial Search Report dated January 25, 2006 (Reference No. 3) received from the European Patent Office. Please note that References D6-D14, cited in the First Office Action issued in Australian Patent Application No. 2002325088 (Reference No. 1), were previously submitted with Applicant's Information Disclosure Statement dated November 9, 2006.

1. Reference No. 8, Sequence ID NO: 7050 of WO 01/075067, was cited in both Search Reports. WO 01/075067 contains a total of 3874 pages, and the tables disclosing sequences are believed to begin on page 99 and end on page 3870. Sequence ID NO: 7050 is referenced on page 819, yet the actual sequence for this sequence identifier is not disclosed in the table. Due to the large size of WO 01/075067, Applicants are only providing pages 1-99, 819, and 3870-3874 of this publication.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,




Xiaochun Zhu
Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

XZ:dg

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)
17530

Application Number
10/800,322

Applicant(s)
Robert James, et al.

Filing Date
March 12, 2004

Group Art Unit
1634

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 00/37643	6/29/00	PCT			✓	
	WO 02/40720	5/23/02	PCT			✓	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

First Office Action issued in respect of corresponding Australian Patent Application No. 2002325088 on October 26, 2005

Supplementary Partial European Search Report dated May 2, 2005

Supplementary Partial European Search Report dated January 25, 2006

SEQ ID NO: 13 of PCT International Publication No. WO 00/55371, published September 21, 2000

SEQ ID NO: 17 of PCT International Publication No. WO 00/76530, published December 21, 2000

Chan E-C, "Identification of Novel Genes that are Differentially Expressed in Human Colorectal Carcinoma", *Biochimica et Biophysica Acta* 1407(3):200-204 (1998), XP-000910494

SEQ ID NO: 7050 of PCT International Publication No. WO 01/075067, published October 11, 2001

SEQ ID NOS: 1047 and 3703 of PCT International Publication No. WO 99/38972, published August 5, 1999

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

P09A/REV04

Patent and Trademark Office*